Madrigal pharmaceuticals to present multiple rezdiffra™ (resmetirom) abstracts in nash/mash at the aasld liver meeting®

Conshohocken, pa., oct. 30, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash)/metabolic dysfunction-associated steatohepatitis (mash), today announced multiple resmetirom data presentations at the upcoming american association for the study of liver diseases (aasld) liver meeting, taking place from november 15-19, 2024 in san diego.
MDGL Ratings Summary
MDGL Quant Ranking